Understanding the Impact of US Tariffs on Australian Pharmaceutical Companies
The recent announcement by the United States regarding new tariffs on imported pharmaceuticals has sparked discussions among Australian drugmakers. While the proposed 100% tariffs could have significant implications, several major companies have expressed confidence that their operations will not be heavily affected.
New Trade War Front
US President Donald Trump’s recent declaration about imposing up to 100% tariffs on imported drugs has raised concerns within the global pharmaceutical sector. However, there are exceptions for companies planning to relocate manufacturing to the US. Additionally, certain countries with trade agreements with the US, such as Japan, South Korea, Switzerland, and the European Union, have tariff caps in place.
CSL Ltd’s Response
CSL Ltd (ASX: CSL), Australia’s largest drug company, has stated that the new tariffs are unlikely to significantly impact its operations. The company emphasized that most of its U.S. product sales would not be subject to these tariffs. CSL also highlighted that the U.S. administration has recognized the unique nature of plasma-derived therapies, which aligns with longstanding policies aimed at ensuring patient access to life-saving treatments.
Key points from CSL’s statement include:
- CSL’s U.S. plasma therapies are derived entirely from U.S. sourced plasma.
- The company continues to invest in manufacturing and job creation in the U.S., recently announcing a $1.5 billion expansion plan for its plasma therapy manufacturing capabilities in Illinois.
- The primary product sold by its Seqirus division in the U.S., Fluad, is manufactured in the UK with a current tariff of 10%, expected to reduce to zero.
Mayne Pharma’s Perspective
Mayne Pharma Ltd (ASX: MYX) also indicated that the new tariffs would not have a material impact on its FY27 earnings. The company noted that there are no tariffs applied to generic medicines and only minimal tariffs on its women’s health portfolio. Additionally, Mayne Pharma produces branded dermatology products in the U.S., meaning no tariffs apply to those items.
Specific details from Mayne Pharma include:
- For the Women’s Health segment, the tariffs would not apply to contraceptives in the branded portfolio.
- Menopause products would not be significantly affected, as only one active pharmaceutical ingredient (API) is sourced internationally, and that API comes from a territory under an existing trade deal with the U.S.
Market Reactions
Following the announcements, CSL shares saw an increase of 2.1% in early trade, reaching $141.94. Similarly, Mayne shares rose by 2.6%, trading at $2.39.
Conclusion
While the new U.S. tariffs on pharmaceutical imports have raised questions, both CSL Ltd and Mayne Pharma have indicated that their operations are likely to remain unaffected. Their responses highlight the importance of strategic planning and existing trade agreements in mitigating potential impacts. As the situation evolves, it will be crucial for investors and stakeholders to monitor further developments closely.
